| Product | Ursodeoxycholic Acid (UDCA) |
|---|---|
| CAS | 128-13-2 |
| Typical MOQ | 25–50 kg |
| Packaging | 25 KG/DRUM |
| Lead Time (typical) | 4–8 weeks (stock); 8–12 weeks (production) |
| Key Production Regions | Shandong, Jiangsu, Zhejiang, Tianjin |
| Share of Global UDCA Supply | Estimated >70% from China |
China supplies the majority of the world's pharmaceutical-grade ursodeoxycholic acid (UDCA) API. For procurement professionals, regulatory specialists, and quality assurance teams sourcing UDCA from Chinese manufacturers, this guide provides a structured approach to supplier evaluation, compliance verification, and risk management in the 2026 procurement environment.
China's structural position in UDCA manufacturing stems from an integrated supply chain that no other region has replicated at comparable scale. The synthetic route to UDCA starts from cholic acid, which is extracted from bovine bile — a byproduct of China's domestic beef industry, the largest in the world by volume. Chinese manufacturers access this starting material at costs that are structurally lower than those of competitors in Europe, India, or North America.
The transition from bear bile extraction to fully synthetic UDCA production occurred in China during the late 1990s and early 2000s. Several Chinese steroid API manufacturers invested in dedicated UDCA production lines with annual capacities in the tens of metric tons. By 2020, an estimated over 70% of the world's pharmaceutical-grade UDCA API originated from Chinese facilities. This concentration has implications for global supply security — any significant disruption to Chinese UDCA production (regulatory, environmental, or trade-related) would affect formulators and generic pharmaceutical companies worldwide.
UDCA API production is concentrated in a small number of Chinese provinces with established steroid chemistry infrastructure:
When evaluating a UDCA supplier, the specific manufacturing site is more important than the province. Always verify the site's current GMP status and regulatory filing history independently.
GMP (Good Manufacturing Practice) certification is non-negotiable for pharmaceutical-grade UDCA procurement. However, the term "GMP certified" lacks a universal definition in China. Buyers must verify which specific GMP standard applies:
When a supplier claims GMP certification, request a copy of the current certificate. Verify the issuing authority, the facility name and address (matching the actual production site), the product scope, and the validity date. A certificate that is expired, that lists a different legal entity, or that does not explicitly cover UDCA production is of limited value. For EU market access, also verify whether the facility holds a valid CEP (Certificate of Suitability) — see the next section.
A Type II DMF filed with the US FDA provides confidential detailed information about the manufacturing facility, UDCA production process, and quality controls. A DMF in "active" status indicates the holder has responded to the most recent FDA review cycle. However, an active DMF does not guarantee that the facility has passed an FDA inspection; the DMF and the inspection are independent processes. Before purchasing UDCA API for use in a US-registered drug product, confirm with the supplier whether the manufacturing site has been FDA-inspected and received a VAI (Voluntary Action Indicated) or NAI (No Action Indicated) classification.
A CEP, issued by the EDQM (European Directorate for the Quality of Medicines & HealthCare), certifies that the UDCA manufacturing process and quality meet the European Pharmacopoeia monograph. CEP holders are subject to periodic GMP inspections by EDQM. A valid CEP for UDCA is the most straightforward way to demonstrate EP monograph compliance for EU marketing authorization. For further detail on CEP significance, see our glossary entries on CEP and GMP.
Verify supplier claims independently using public databases: the FDA DMF database (for DMF listing confirmation), the EDQM Certification database (for CEP validity), and the FDA warning letter database (to check whether the supplier has received recent regulatory actions). A supplier who accurately represents their regulatory status in these databases is a positive signal of transparency.
A supplier audit — whether conducted in person or remotely — is the most reliable way to verify a Chinese UDCA manufacturer's quality system. A structured audit should cover:
Before committing to a commercial order, request an evaluation sample (typically 10–100 g) with a corresponding Certificate of Analysis (CoA). When reviewing a UDCA CoA, focus on the following priority areas:
If the CoA values are at the borderline of acceptance criteria on multiple parameters, this can indicate a process running at the limit of its capability and raises the risk of future out-of-specification results. For detailed guidance on CoA interpretation, see UDCA Quality Standards: USP vs EP Pharmacopoeia.
The following patterns should raise concern during supplier evaluation:
The typical MOQ for UDCA from Chinese manufacturers and trading companies is 25–50 kg, corresponding to 1–2 drums. Some manufacturers may set a higher MOQ of 100 kg for direct supply. Trading companies like KingWish can often accommodate smaller evaluation orders (1–5 kg) by consolidating from stock, which is valuable for initial quality assessment and stability testing.
Stock availability is the primary determinant of lead time. If the supplier has UDCA in stock (the most common scenario for a trading company with regular supply), shipment can be arranged within 4–8 weeks including documentation preparation and logistics. For made-to-order production from a manufacturer, the lead time is typically 8–12 weeks, plus logistics transit time of 1–3 weeks depending on the destination and transport mode (air freight vs sea freight).
Standard payment terms for UDCA procurement from China include telegraphic transfer (T/T) with 30–50% advance payment and the balance before shipment, or letter of credit (L/C) at sight for larger orders. Open account terms are uncommon for first-time transactions. For long-term supply agreements, payment terms typically improve with the established relationship.
Common Incoterms for UDCA shipments from China: FOB (Free on Board) from Shanghai, Qingdao, or Tianjin ports; CIF (Cost, Insurance, Freight) to the buyer's nominated port; and more recently CPT (Carriage Paid To) for consolidated air freight shipments. UDCA is a stable dry powder at ambient temperature and does not require cold chain logistics, simplifying transport compared with biologics and temperature-sensitive products.